Ariad Pharmaceuticals is not considering a sale, but the company is in talks with potential marketing partners in Japan for experimental blood cancer medicine ponatinib, said CEO Harvey Berger. He projected that the drug would create a global market worth more than $600 million annually. Ariad would commercialize ponatinib in the U.S. and Europe without a partner, Berger said.

Full Story:

Related Summaries